Research programme: small molecule therapeutics - Lexicon/Nuevolution

Drug Profile

Research programme: small molecule therapeutics - Lexicon/Nuevolution

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lexicon Pharmaceuticals; Nuevolution
  • Developer Duke University; Howard Hughes Medical Institute; Lexicon Pharmaceuticals; Nuevolution
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 21 Sep 2015 Nuevolution has patent protection for Chemetics® technology throughout world
  • 13 Jan 2014 No development reported for Undefined indication in Denmark (unspecified route)
  • 13 Jan 2014 No development reported for Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top